Neoinsurance Unicorn Public Meltdown: A Quick Check-In

The Shift in Insurtech Valuation

A recent period saw insurtech startups directly offering insurance products garner significant attention and investment in both private and public markets. However, the landscape has undergone a notable transformation.

The transition of venture-backed insurtech companies to public markets was a prolonged process. Lemonade, specializing in rental insurance, debuted on the public market in early July 2020. Root, concentrating on auto insurance, followed in October of the same year.

Early Public Offerings

Metromile, another player in the auto insurance sector, went public through a SPAC merger in February 2021. Subsequently, Hippo, focused on home coverage, completed its public listing via a blank check company in August of the following year.

These companies experienced a period of substantial liquidity following considerable venture capital funding during their initial stages.

Public Market Performance

Since their initial public offerings, the public markets have presented challenges. Metromile announced its acquisition by Lemonade after a significant decline in its value. Currently, Metromile's stock is valued at approximately $2 per share, a substantial decrease from its 52-week high of just over $20 per share.

Comparable companies have also faced difficulties. Lemonade has witnessed its share value decrease from a peak of over $188 to $38.68 as of this writing. Root's stock is currently trading at $3.16 per share, down from a 52-week high of $25.63. Hippo has fallen to $2.62 per share from its peak of $15 per share. These developments have been closely monitored in recent quarters.

Oscar Health's IPO

Oscar Health, a consumer health coverage provider, also had a notable initial public offering. Initial assessments of its pricing were critical.

While tracking post-IPO valuations of several so-called neoinsurance providers focused on auto and home insurance, Oscar Health was initially excluded from regular monitoring. Let's revisit the accuracy of the initial perspective on the company’s IPO pricing.

The initial pricing, it should be noted, appeared questionable even at the time. The company priced its shares at $39, and its performance since has been as follows:

Expectations vs. Reality

A peculiar aspect of the neoinsurance companies that went public is that their financial performance was often underwhelming at the time of their offerings. Market expectations perhaps anticipated a more rapid and substantial impact from the technological components of these startups on their profitability.

The assumption was that significant investment in technology and modern tools would lead to improved underwriting models, more accurate insurance pricing, and efficient customer acquisition through digital-first applications.

Current Situation and Lessons Learned

Despite the challenging environment, many of these neoinsurance companies remain financially stable and possess the resources to navigate the current economic downturn. However, it is evident that the private markets overestimated the value of certain insurtech startups, and the public markets were initially swayed by this perception.

The subsequent outcome has been unfavorable, with individual investors experiencing losses on some of these companies. The situation highlights a crucial lesson: companies that make excessive claims and demonstrate poor performance are likely to be unreliable.

The neoinsurance unicorn public market downturn, including the case of Oscar Health, reinforces an age-old principle: appearances can be deceiving.